ArticleBMC cancer2020

Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.

Maryam Soleimani Dodaran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.